Parkinsons Disease Management in Primary Care. Introduction Progressive condition 1:500 whole population 1:50 of elderly 1:10 Nursing Home Residents.

Slides:



Advertisements
Similar presentations
Pharmacological Management of Parkinson’s Disease
Advertisements

Parkinson Disease (PD) Treatment Update. Outlines The Basics: – PD Introduction and motor symptoms. – DDx not to miss. – Different classes of Anti PD.
Parkinson’s disease Dartington 26 June 2003
Drugs That Act On The Central Nervous System SAMUEL AGUAZIM( MD)
PALLIATIVE CARE An overview.
Parkinson’s Finding the cure Presentation
Parkinson's Disease Animal Models and Possible Treatments.
Diagnosis and Management of Parkinson’s Disease
ILOs At the end of this lecture you will be able to:- Recognize the symptoms and pathophysiology of parkinsonism. Understand the pharmacology of drugs.
Parkinson’s Disease (PD)
The PARticulars of Parkinson’s Disease
Parkinson’s Disease Dr Rachel Cary, Warwick Hospital.
Neurology and Rehabilitation Target Day Parkinson’s Disease Dr Bruce Covell Amanda Horlor Linda Lloyd.
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
Initial Diagnosis and Management of Parkinson’s Disease
Is it a neurodegenerative brain disorder that progresses slowly in most people.
Erica Partridge Parkinson’s Disease. Definition Aetiology PD vs Parkinsonism Symptoms and signs Differentials Investigations Management Prognosis.
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
Parkinson’s Disease By Devin Cornford
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 16 Antiparkinsonian Drugs.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Chapter 30 Agents Used to Treat Parkinson’s Disease.
SYMPTOM CONTROL IN ADVANCED PARKINSON’S DISEASE Vicky Travers PDNSUHMBT April 2012.
Improving life and end-of-life care in advanced neurological conditions: The Rehabilitation Perspective Rory O’Connor MD Consultant Physician in Rehabilitation.
Drugs for Parkinon’s disease Parkinson's disease –progressive tremor –Bradykinesia and rigidity –degeneration of the dopaminergic nigrostriatal pathway.
The management of advanced Parkinson’s disease Dr J Paul Milnes Consultant Physician Airedale NHS Trust.
Antipsychotic drugs. Anti-psychotic drugs The CNS functionally is the most complex part of the body, and understanding drug effects is difficult Understanding.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
By Prof. Hanan Hagar Pharmacology unit Medical College.
CONTINENCE ISSUES IN PEOPLE WITH PARKINSON’S DISEASE The role of the Field Officer.
Adult Medical-Surgical Nursing Neurology Module: Parkinson’s Disease.
Salvador Dali (Painter) Mao Zedong (Chinese Politician) Michael J Fox (Actor) Pope John Paul II Muhammad Ali (Boxer) Janet Reno (Former AG)
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Represented by SHIVAJI SINGH SAMEER CHAVAN SOURIMA MUKHERJEE SONAL KULKARNI SUVARNA CHAVAN M.Sc (CLINICAL RESEARCH) (CRANFIELD)GROUP-9.
Slide 1 Mosby items and derived items © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 15 Drugs Used for Parkinson’s Disease.
Drugs used in parkinsonism
By Prof. Hanan Hagar Pharmacology unit Medical College.
ANTIPSYCHOTICS Katy and Zoë. Psychosis Mental disorder with a broad range of symptoms. Patients ‘lose touch with reality’ and present with: hallucinations.
By Prof. Hanan Hagar Pharmacology unit Medical College.
Parkinson's Disease ILOs
Parkinson's disease By Colby Allen. symptoms Mild to major tremors. Rigidity or joint stiffness Bradykinesia or slowness of movement Postural instability.
Drugs in parkinsonism ilos
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Parkinson’s Disease Angela Duncan June Why I Chose This Subject Common neurodegenerative disorder / in Scotland Expected increase.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
ANTI- PARKINSONISM Dr: Samah Gaafar Al-shaygi.  Neurodegenerative diseases.  Dopamenergic neurones in substantia nigra.  Environmental* genetic factors.
 Parkinson’s disease is a neurodegenerative disorder first described by Dr James Parkinson, a London physician, in The underlying cause is loss.
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
ANTI-PARKINSONIAN DRUGS. Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.
Early Intervention in Dementia Bernie Coope Consultant Old Age Psychiatrist/Associate Medical Director/Honorary Senior Lecturer, Worcester Association.
Parkinson's disease.
Drugs Used for Parkinson’s Disease
Parkinsonism.
Understanding Parkinsons Disease
MOVEMENT DISORDERS.
Lecture 3 Dr.Narmin Hussen
Drugs for Parkinson’s Disease
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
ANTIPARKINSONS Drugs By Dr. Mirza Shahed Baig.
Drug-induced dyskinesias
Central Nervous System
Parkinsonism and Anesthesia
Diagnosis Stage Parkinson’s Disease (PD) Guidelines
מחלת פרקינסון מחלת פרקינסון היא מחלה Progressive.
Drugs for Degenerative Diseases of the Nervous System
Classification of Epilepsy (p. 227)
Pharmacological Management of Parkinson’s Disease
Neurodegenerative diseases
Management in Primary Care
Lorna Gillies Parkinson’s Nurse Specialist
Presentation transcript:

Parkinsons Disease Management in Primary Care

Introduction Progressive condition 1:500 whole population 1:50 of elderly 1:10 Nursing Home Residents

Recognition Slowness Stiffness Tremor Loss of balance

First Diagnosis PCT priorities carer support manage co-morbidity nursing needs assessment Patient concerns driving (DVLA, insurers) inheritance (rare)

Management Aims Initial acceptance of diagnosis control symptoms reduce distress improve outlook Subsequent relieve morbidity prevent complications

Maintenance PCT priorities complications follow-up arrangements ?shared care Patient concerns work/finance/benefits sexuality

Complex Parkinsons PCT priorities Aims maintain good health manage drug regime address disease/complication problems support for patients/carers

Complications Deteriorating function immobility, slowness, loss of activity Loss of drug effect end-dose, on-off effects Involuntary movements (dyskinesia) Confusion, depression, hallucination Constipation, incontinence, wt loss, hypotension

Referral Initial Maintenance Complex Palliative

Referral: Initial Confirmation of diagnosis Management multi-disciplinary team see later drug treatment Special Interest follow-up monitoring side effects

Referral: Maintenance Multi-disciplinary team Occupational Therapy Physiotherapy Dietician Speech/Language therapy Social Services Podiatrist Continence Advisor

Referral: Complex Specialist team in major role access to secondary care neurosurgery watch for complications communication

Referral: Palliative Appropriate support palliative care services social needs assessment care in home, nursing home or hospice

Drug Treatment Progression PD inevitably progresses Tachyphylaxis Levodopa only works for 4-5 years More levodopa = late side effects 50% of patients by 4-5 years Polypharmacy

Drug Treatment Levodopa Dopamine agonists Selegiline (MAOI type B) COMT inhibitors Anticholinergics Amantadine

Levodopa used since 1960s mixed with dopa decarboxylase inhibitor good for rigidity/bradykinesia not so good for tremor Side Effects: confusion, hallucinations, mood changes/swings involuntary movements: on-off

Dopamine Agonists Bromocriptine, Pergolide, Ropinirole, Cabergoline, Pramipexole single Rx co-Rx with levodopa Apomorphine subcutaneous injection in advanced refractory disease usually initiated in-patient (ADR)

Selegiline MAOI prevents Dopamine breakdown co-Rx with levodopa unexpectedly high mortality (?autonomic ADR)

COMT inhibitors Inhibit alternative dopamine degradation pathway Allow reduction levodopa dose (30- 50%) LFTs need to be monitored

Anticholinergics Benzhexol, orphenadrine useful in younger patients with tremor avoid in elderly (ADR)

Amantadine Useful in younger/mildly-affected patient Loses effect quickly (months) Good for mild akinesia/tremor

Drugs to avoid Phenothiazines Prochlorperazine, fluphenazine, haloperidol, sulpiride Metoclopramide MAOIs: provoke ADR with levodopa Atypical antipsychotics clozapine, olanzapine

Parkinsons Disease Society 215 Vauxhall Bridge Road, LONDON SW1V 1EJ Tel Helpline